OF ALL THE medical challenges that scientists have confronted, Alzheimer’s illness, the commonest type of dementia, has been one of many trickiest. Between 1995 and 2021 non-public cash spent on Alzheimer’s analysis totalled $42.5bn, however greater than 140 trials did not ship a single drug able to slowing the illness. But the tide could also be turning. There are two working medication, providing modest advantages, available on the market. A brand new evaluation paper suggests extra might quickly observe.
